%D9%81%D9%84%D9%88%D8%AF%D8%A7%D8%B1%D8%A7%D8%A8%D9%8A%D9%86%D9%81%D9%84%D9%88%D8%AF%D8%A7%D8%B1%D8%A7%D8%A8%DB%8C%D9%86Category:FludarabineFludarabinFludarabineFludarabina%D9%81%D9%84%D9%88%D8%AF%D8%A7%D8%B1%D8%A7%D8%A8%DB%8C%D9%86FludarabiiniFludarabine%D7%A4%D7%9C%D7%95%D7%93%D7%A8%D7%91%D7%99%D7%9F%E3%83%95%E3%83%AB%E3%83%80%E3%83%A9%E3%83%93%E3%83%B3%E0%AC%AB%E0%AD%8D%E0%AC%B2%E0%AD%81%E0%AC%A1%E0%AC%BE%E0%AC%B0%E0%AC%BE%E0%AC%AC%E0%AC%BF%E0%AC%A8FludarabinaFludarabin%C4%83%D0%A4%D0%BB%D1%83%D0%B4%D0%B0%D1%80%D0%B0%D0%B1%D0%B8%D0%BDFludarabinFludarabinFludarabin%D0%A4%D0%BB%D1%83%D0%B4%D0%B0%D1%80%D0%B0%D0%B1%D1%96%D0%BDFludarabineQ185916
about
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid LeukemiaA Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid LeukemiaA Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) MutationDosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid MalignanciesCytokine-Treated Veto Cells in Treating Participants With Hematologic Malignancies Following Stem Cell TransplantTCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated DonorsDonor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched DonorsStudy of Clofarabine and Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT)Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell TransplantationT Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple MyelomaStudy of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHLA Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi AnemiaHaplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical TransplantationThe ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) TrialAllogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell LymphomaPilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid TumorsNonmyeloablative Allo SCT for the Treatment of Hematologic DisordersEL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNon-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood DisordersFludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaSMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic LeukemiaStem Cell Transplant (SCT) for Dyskeratosis Congenita or SAACombination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesFludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi AnemiaOxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLLDonor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood DiseasesMini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast CancerResearch Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell TransplantationConditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell TransplantationA Pilot Study of HSCT for Patients With High-risk Hemoglobinopathy Using a Nonmyeloablative Preparative RegimenCellular Therapy With Cord Blood CellsPurine Analog-Based Conditioning in Patients With Severe Aplastic AnemiaDonor Stem Cell Transplantation for Congenital ImmunodeficienciesChemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaUmbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other DiseaseAllogeneic Blood Stem Cell TransplantationCombination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
P4844
Enhanced efficiency of prodrug activation therapy by tumor-selective replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene.Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipientsAccurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipientsCytotoxic activity of 2-Fluoro-ara-AMP and 2-Fluoro-ara-AMP-loaded erythrocytes against human breast carcinoma cell lines.Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate.Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma.In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics.Successful treatment of cutaneous intravascular large B-cell lymphoma with fludarabine phosphate.[Successful treatment of T-cell prolymphocytic leukemia (T-PLL) with fludarabine monophosphate].CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid MalignanciesCD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory NeuroblastomaAllogeneic Transplantation Using Timed Sequential Busulfan, Cladribine, and Fludarabine Conditioning in Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)CD19+ CAR T Cells for Lymphoid MalignanciesAllogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular LymphomaAutologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATGFludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and ThymoglobulinAzacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)Busulfan and Fludarabine Followed by Post-transplant CyclophosphamideFludarabine, Cyclophosphamide, and Rituximab - High Dose FrontlineRomidepsin Maintenance After Allogeneic Stem Cell TransplantationCord Blood Natural Killer (NK) Cells in Leukemia/LymphomaCyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Non-Myeloablative Allogeneic Stem Cell TransplantationCloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic MalignanciesAlloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's DiseaseLymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic MelanomaBusulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid LeukemiaRadiation Therapy Plus Fludarabine in Treating Patients With Locally Advanced Cancer of the Mouth, Pharynx, or LarynxSafety and Efficacy of Campath in Nonmyeloablative TransplantationAllo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDSSafety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies
P921
Q61694869-A99F2362-A5C8-4573-B971-EC63786E5AF4Q61700075-E25951FC-0A27-45D4-B698-D453B5CA697DQ61862222-A9A8557D-F8EA-41B3-97F6-94D74247E773Q61862273-94FC86C1-F94D-47B3-A5CE-6D4A64780B3BQ61894509-12F9A90E-F331-4926-ABC5-4B6793EA5755Q61902423-1A2A59AA-57B2-47A2-9BA9-1CEDA04D8348Q61904950-4BE2E4AE-9C47-4A50-AE2A-8D415CBD50AAQ61904952-D0FCD3AD-3712-4AA5-8099-F70567296BA5Q61906927-8AB8D58D-CD19-4CFE-AB3D-6B7B265F0652Q61907523-9FB2FFF2-DD69-40B2-8809-BD418E98A50FQ61907543-44F8CCF8-C3C5-43C6-A569-31083FB4C16CQ61907575-8D0F85B7-9080-40DE-9C1A-6719CF2CF351Q61907674-D7323387-AC46-4F28-81BF-B49980156639Q61907988-52D6504A-96E4-4C51-8B7C-D92614F6F18FQ61909338-77F1C788-3CED-400B-833F-C427FE704F1AQ61909393-8FE8BF9D-F1BB-4087-815F-F266E1C3E68EQ61914538-090259DC-AE79-4D30-AEE9-447F7D8721C1Q61914857-9E16A36E-4857-44EC-96C4-063D2819F840Q61914887-A826E68F-6AB5-4B52-98ED-7C70CD29915EQ61915285-1BDDC8F8-FD34-44BD-912F-EE4CD9906347Q61915350-E9DF24E9-A1E5-47FD-89F3-C740BFEF2EA6Q61918157-1694F4CC-5CBB-46DB-B5BC-D9A8DE7F0694Q61918213-1AB47510-06EC-458E-B73B-CD236D87C030Q61918327-8970F74C-6EF0-44EF-8DA6-DB3BC2ADE491Q61920640-63E4431D-5D1F-4E5C-B08C-3DF633E42A38Q61920712-855F0BFA-1D0E-48BF-9814-ACA6DD30BD93Q61920801-9B993EF1-6656-4946-B67A-0A58B935BAAEQ61920880-ADE44FEC-0880-436A-95DA-87259B8359DEQ61921024-856A0094-26E1-43BD-81CB-997B0ED80806Q61921177-205E3CA0-D812-4D46-8A0B-3A43C0720A31Q61921189-E6E44710-370D-433F-B4A4-205EE642744EQ61921221-994099B0-DCCD-4554-A968-07A95B766DBDQ61921334-56494EF2-D0F9-4B18-9962-437E91C3807CQ61921343-8477BC14-C9B0-420C-B1B0-5815C30F7F7FQ61921359-74284AF2-8C43-4F2F-ABD2-339B53DA9417Q61921428-2F36B1DF-B863-49F1-A8FD-D3A65A18CE41Q61921484-CD56CB89-1E13-4908-81A2-7EDD6B69F6E1Q61921654-0190BC89-CE06-45C0-BA63-A366DF5B8130Q61921672-88AF4549-D0B5-4211-9457-7F70F9DE8D4EQ61922344-DA111ECE-7633-4A8E-80FF-A841041CF02E
P4844
Q34124630-C8EC77C5-0A8B-4433-B340-4768AE83C7F3Q35100217-EABF8620-6CCD-4403-A2E6-250668A264CFQ35760706-30A01384-E8F8-46EF-B1BB-6BB24F08489BQ37070285-55214B41-B875-4D90-8D16-A385BF0064E6Q39698130-E50F53DB-8289-4D4E-BA3C-56D9C5537319Q39905474-85E8E3CE-08DC-4E3C-B5E1-DBDF2A384A75Q40762954-9BEAA40A-5C86-4AEC-B3A6-05A7AA831412Q40893626-52E22FA8-9747-432D-90AE-FF2ADE7E4A71Q42080758-D26483AB-B282-4BC5-B694-213289AC6E8EQ43136898-D4D74AB9-7F30-4D2F-8658-73ED33726EF4Q43241840-39F0AE6C-3552-4920-9ABB-43D4FFEAAA47Q63838088-295F0FC4-A9E4-4104-A3C4-E766E4EF40E7Q64029938-B13DBE99-F7B1-4FB8-95CC-A63D087A0F73Q64043386-25F219CA-2838-4C75-80BC-2825C9BBEF21Q64150371-0F927211-807B-4B3D-B9DC-B11212DA5760Q64151601-985C5552-7635-4A3F-B345-47EFDF0C02ADQ64151677-4A8E7EBE-0757-4716-91C0-D7CB2DAE06BCQ64171003-05C5043C-BCB0-423A-A6C0-D7F17C067CA2Q64610663-1992F8E3-135E-46DF-9822-B073107C7A53Q64647421-2919396D-84C3-4CDF-A69B-9CB670D24ABAQ64650272-4E658E10-2902-4C3D-9B41-E3F0FECBAF26Q64658667-280F5E4D-2503-4D09-B50C-B23D89FC0A40Q64665704-210C428E-4619-417C-9895-62547E41FC6DQ64694769-D7F55D4B-F7D2-468E-B6F1-24B367B89FB7Q64697051-747CCA86-7676-47B1-903A-5E54AB961829Q64709063-7EE9E070-F766-48A4-95FD-9B29CE3FAACFQ64709538-D7A3EF98-16DE-4FF6-A405-BF864D11859CQ65337433-6CA829AA-1DE1-430C-B1CD-6C1BD8B74545Q65351414-EC21C3F4-B3D5-4AE3-A548-886A1D4EDCB0Q65376729-EBD90D97-6E6F-4385-8488-36C3514C92EDQ65381812-72EAFBC2-127B-4E36-BA59-637D103DA367Q65382448-C1A6C1C3-B38E-47FF-91DD-AF08DB16670CQ65385640-6773B582-AF12-446E-85F3-9218C34BDC10Q65387125-EC3A2EA9-8509-451C-AC20-1A08F1ED6937Q65389539-1DC52DBF-86E2-407C-9DFA-9A172DF1B46AQ65471351-86DA9175-E3A4-43A0-B3C6-F87EBEEB2E91Q66033458-9B80CB5D-7643-468B-8D70-4725222D91D5Q66038358-326710DE-028D-43E9-8BB1-DC23627184BFQ66038360-0015036C-CA8F-483D-823C-FABDD0010B70Q66039489-7F79009D-B660-4ABC-95B0-4C8F5BACC6AE
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Fludarabiini
@fi
Fludarabin
@sh
Fludarabin
@sl
Fludarabin
@sr
Fludarabin-Phosphat
@de
Fludarabina
@es
Fludarabina
@pl
Fludarabine
@nl
Fludarabine
@vi
Fludarabină
@ro
type
label
Fludarabiini
@fi
Fludarabin
@sh
Fludarabin
@sl
Fludarabin
@sr
Fludarabin-Phosphat
@de
Fludarabina
@es
Fludarabina
@pl
Fludarabine
@nl
Fludarabine
@vi
Fludarabină
@ro
altLabel
2-Fluoro-ara AMP
@en
2-Fluoroadenine arabinoside 5'-monophosphate
@en
2F-Ara-AMP
@en
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
@en
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
@en
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
@en
FAMP
@en
Fludara
@en
Fludarabine 5'-monophosphate
@en
Fludarabine Phosphate
@en
prefLabel
Fludarabiini
@fi
Fludarabin
@sh
Fludarabin
@sl
Fludarabin
@sr
Fludarabin-Phosphat
@de
Fludarabina
@es
Fludarabina
@pl
Fludarabine
@nl
Fludarabine
@vi
Fludarabină
@ro
P31
P486
P592
P6366
P646
P661
P662
P665
P683
P1579
P2017
C1=NC2=C(N1[C@H]3[C@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)N=C(N=C2N)F
P2067
P2115
N0000148119
P2275
Fludarabine
@en